(Date:9/4/2008)...imumab to be Presented, PRINCETON, N.J., Sept. 4 ...MEDX ) announced today that nine clinical abstract...ntibody, in melanoma are scheduled to be,the subje...ropean Society,for Medical Oncology (ESMO) being h...e following abstracts will include updated one-yea...
(Date:9/3/2008)...hildren Studied. Wrong,Conclusions Reached., NIXA...s for Disease,Control and Prevention (CDC) study r...MMR vaccine and autism. The National Autism Associ... the growing public concern over a,vaccine-autism ... design,and methodology., For years, parents have...
(Date:9/3/2008).../- Artelis SA and,Selexis SA announce...tibody,production with the achievement of manufact...rd level was accomplished by applying two highly,i...ble Selexis CHO,production cell line rapidly gener...using their proprietary Selexis Genetic Elements(T...
(Date:9/3/2008)...idence Pycnogenol(R) Lowers Joint, Pain, Symptoms;...essation of the Extrac...ng to the Center for,Disease Control (CDC), osteoa... the rise. A new study published in the August jou...R), bark extract from the French maritime pine,tre...
Breaking Medicine Technology:Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3CDC Misses Target With Flawed MMR/Autism Study 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award 1403 1Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award 1403 2Elbit Medical Imaging Ltd Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore India 1401 1Elbit Medical Imaging Ltd Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore India 1401 2Elbit Medical Imaging Ltd Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore India 1401 3Elbit Medical Imaging Ltd Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore India 1401 4SPO Medical Announces Major Sales Milestone 1399 1SPO Medical Announces Major Sales Milestone 1399 2SPO Medical Announces Major Sales Milestone 1399 3Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs Angiographic Guidance of Stent Deployment in Patients with Multivessel 587 1Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs Angiographic Guidance of Stent Deployment in Patients with Multivessel 587 2... - Pfizer announced today,that Lipitor (atorvastat...ke, coronary heart disease events and major corona...nown coronary heart disease,but who had experience...acebo. The results are from a new analysis of the ... in Cholesterol Levels,(SPARCL) trial, and were pr...
...re/ -- Novagali Pharma, an,emerging pharmaceutical...itive results of its pivotal phase III clinical tr...tudy of Vekacia(R) in,children suffering from Vern...n Congress of ophthalmology (AACO) held from June ...evere form of chronic allergic conjunctivitis,char...
Other Medicine Technology:Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 2Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4(Date:9/5/2008)...Most can be controlled, but you need to know what ...Sept. 5 (HealthDay News) -- If you are one of the ...rgies, there is nowhere in the United States that ... a new report shows. , Allergies don,t only hap... seasons as well. In the fall, the most challengin...
(Date:9/5/2008)... FRANKLIN, Mass., Sept. 5 /PRNewswire/ -- Arthr...he developer of less-invasive joint,resurfacing sy...m the U.S.,FDA to begin its pivotal investigation ...he FDA stated that "there are no outstanding safet...initiation., Arthrosurface has been evaluating th...
(Date:9/5/2008)... ,The National Institute of Diabetes and Digesti...al Institutes of Health (NIH), announces awards to...orative studies of urologic chronic pelvic pain di...nd prostate. The total research investment for the...million. , "The launch of this novel research ef...
(Date:9/5/2008)... MIDLOTHIAN, Va., Sept. 5 /PRNewswire/ -- On Sa...ll be featured on the Oxygen Network show Today,s,...ARI is highlighted as a,leading medical device com...s, with effective nebulizers and compressors that ... "Our vision is to improve the lives of those aff...
Breaking Medicine News(10 mins):Health News:No Place Safe From Allergies 2Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2Health News:NIH launches unique effort to advance study of urologic chronic pelvic pain disorders 2Health News:NIH launches unique effort to advance study of urologic chronic pelvic pain disorders 3Health News:PARI Respiratory Equipment Featured on Oxygen Network 2...d multidimensional diagnostic system that elevates...t topography systems which scan the surface of the...ver 9000 data points in 1.5 seconds to meticulousl...yze elevation and curvature measurements on both t...
Trusted technology. Precisely measured. Zywave® II Wavefront Aberrometer offers precision diagnostics, measuring refractive error by identifying the total aberrations of the eye. ,As part of the
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e
RELIEF® eye drops quickly remove redness due to dust, smoke & other pollutants and provide protection against further irritation from wind and the sun. This unique formula contains the effective
Medicine Products: